-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our target to $612 from $620, based on 37.3x our 2027 EPS estimate, below IDXX's historical forward P/E averages. We slightly raise our 2026 EPS view to $14.70 from 14.67. We keep our 2027 view at $16.42. IDXX reported a solid Q1, exceeding expectations, with revenue of $1.141B (+11% Y/Y organic) due to strong performance in its Companion Animal Group Diagnostics recurring revenue. However, we see IDXX facing risks in the near term stemming from macroeconomic pressures on consumers that are causing a decline in discretionary wellness-related veterinary visits. This trend poses a financial risk, as IDXX full-year guidance assumes a 1.5% decline in U.S. clinical visits; thus, a further worsening of the economic environment could lead to steeper declines and challenge revenue targets. Additionally, IDXX flagged a minor supply chain disruption in the Middle East, which, while contained, underscores the potential for broader operational risks within global business activities.